Diffusion of metioprim, tetroxoprim and sulphadiazine in the cerebrospinal fluid of dogs with healthy meninges and dogs with experimental meningitis.
The diffusion of metioprim (MTP), tetroxoprim (TXP) and sulphadiazine (SDZ) in cerebrospinal fluid (CSF), following single intravenous doses and continuous infusions, was studied in dogs. The drugs penetrated well into the CSF of animals with and without experimental Staphylococcus aureus meningitis. In dogs with healthy meninges, the CSF bioavailability - expressed as the ratio of CSF/plasma area under the curve 0-5-hour values - following continuous infusion was determined to be 86.7% for MTP, 58.2% for TXP and 38.8% for SDZ. In infected animals, CSF availability following continuous infusion increases slightly to ratios of 96% (MTP), 70% (TXP) and 50% (SDZ). For all drugs, the concentrations reached in CSF were above the minimum inhibition concentrations for the majority of Enterobacteriaceae, indicating their potential value in treatment of gram-negative bacillary meningitis.
D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000134:cerebrospinal fluid*; D001812:Blood-Brain Barrier; D004285:Dogs; D005260:Female; D006207:Half-Life; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D007700:Kinetics; D008297:Male; D008581:Meningitis / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D011743:Pyrimidines / Q000008:administration & dosage / Q000134:cerebrospinal fluid*; D013203:Staphylococcal Infections / Q000134:cerebrospinal fluid / Q000188:drug therapy; D013411:Sulfadiazine / Q000008:administration & dosage / Q000134:cerebrospinal fluid*; D014295:Trimethoprim / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000134:cerebrospinal fluid
D000890:Anti-Infective Agents; D011743:Pyrimidines; D013411:Sulfadiazine; C023507:tetroxoprim; D014295:Trimethoprim; C036263:metioprim